Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study

Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study

ABSTRACT Advanced‐stage EGFR‐mutated lung non‐small cell lung cancer (NSCLC) challenges current treatment paradigms, particularly after frontline EGFR‐TKI therapy failure. This study investigates the survival impact of combined anti‐angiogenic agent and immunochemotherapy (AICT) for this population....

Full description

Saved in:
Bibliographic Details
Main Authors: Yi‐Tse Su, Shu‐Farn Tey, Chung‐Ta Lee, Chien‐Yu Lin, Jeng‐Shiuan Tsai, Chien‐Chung Lin, Chin‐Wei Kuo
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Kaohsiung Journal of Medical Sciences
Subjects:
anti‐angiogenic agent
EGFR mutation
immunotherapy
NSCLC
survival
Online Access:https://doi.org/10.1002/kjm2.70023
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.1002/kjm2.70023

Similar Items